Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 6;10(19):6349-6359.
doi: 10.12998/wjcc.v10.i19.6349.

Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea

Jun-Hyung Cho  1 , So-Young Jin  2
Affiliations
Review

Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea

Jun-Hyung Cho et al. World J Clin Cases. .

Abstract

Helicobacter pylori (H. pylori) infection is highly prevalent in East Asia. The overall seroprevalence rate of H. pylori infection is 44.2% in China, 37.6%-43.2% in Japan, and 51.0% in South Korea. H. pylori can cause peptic ulcer disease and gastric cancer. East Asian countries have high rates of gastric cancer (age-standardized incidence rate: 20-30 per 100000). The Kyoto global consensus report emphasized that H. pylori gastritis should be considered the main cause for the development of gastric cancer. H. pylori treatment guidelines in China, Japan, and South Korea have recently been revised according to data from each of those countries. However, emerging antibiotic resistance is an important barrier to H. pylori eradication. The recommended H. pylori treatment regimens differ among those three East Asian countries. In this review, recent guidelines and up-to-date research on H. pylori treatment regimens from China, Japan, and South Korea are discussed.

Keywords: Antibiotic resistance; China; Helicobacter pylori; Japan; South Korea; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Prevalence of primary Helicobacter pylori resistance to antibiotics in China, Japan, and South Korea. CAM: Clarithromycin; MDZ: Metronidazole; LVFX: Levofloxacin; AMX: Amoxicillin; TET: Tetracycline.
See this image and copyright information in PMC

References

    1. Crowe SE. Helicobacter pylori Infection. N Engl J Med . 2019;380:1158–1165. - PubMed
    1. Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett . 2014;345:196–202. - PubMed
    1. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology . 2017;153:420–429. - PubMed
    1. Ren S, Cai P, Liu Y, Wang T, Zhang Y, Li Q, Gu Y, Wei L, Yan C, Jin G. Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis. J Gastroenterol Hepatol . :2021 Dec 3. - PubMed
    1. Ueda J, Gosho M, Inui Y, Matsuda T, Sakakibara M, Mabe K, Nakajima S, Shimoyama T, Yasuda M, Kawai T, Murakami K, Kamada T, Mizuno M, Kikuchi S, Lin Y, Kato M. Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. Helicobacter . 2014;19:105–110. - PubMed